Standard Active Last Updated: Dec 12, 2024 Track Document
ASTM E3443-24

Standard Guide for Minimizing the Impact of Stability Testing on Batch Yield of Low Yield Biopharmaceutical Products

Standard Guide for Minimizing the Impact of Stability Testing on Batch Yield of Low Yield Biopharmaceutical Products E3443-24 ASTM|E3443-24|en-US Standard Guide for Minimizing the Impact of Stability Testing on Batch Yield of Low Yield Biopharmaceutical Products Standard new BOS Vol. 14.01 Committee E55
$ 69.00 In stock
ASTM International

Significance and Use

5.1 Stability studies are important in biopharmaceutical product development and they are required by regulatory agencies. The “stability tax” is particularly significant for products whose processes have low yields. Stability studies and sample use plans must be optimized to allow for proper execution of both stability and clinical aspects of product development.

5.2 Appendix X1 provides an example of stability sample optimization for a mock rAAV process. The example shows that product savings of up to 17 % of a drug substance (DS) batch and 44 % of a drug product (DP) batch relative to the baseline protocol may be possible.

Scope

1.1 The intent of this guide is to discuss and provide recommendations for reducing the volume requirements for the stability assessment of low yield biopharmaceutical products.

1.2 The recommendations include considerations for both drug substance (DS) and drug product (DP).

1.3 The scope of this guide may be applicable to any modality that has yield constraints or small batch size, however the example provided is specific for rAAV gene therapies.

1.4 The need for specific recommendations for low yield biopharmaceutical products has been identified by observing that stability guidance (for example, ICH Q1 and ICH Q5) are mainly designed for large-scale biologic/small molecule products and are not fully applicable to the unique specificities of low yield products (for example, gene therapy). The recommendations focus on strategies for routine stability studies. Development and supporting studies such as freeze/thaw stability are excluded from the scope of this guide.

1.5 Before application to specific products, companies should ensure internal alignment with the proposed approach, including a documented scientific rationale, and discuss as appropriate with applicable regulatory agencies.

1.6 Units—The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.7 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.

1.8 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

Price:
Contact Sales
Related
Reprints and Permissions
Reprints and copyright permissions can be requested through the
Copyright Clearance Center
Details
Book of Standards Volume: 14.01
Developed by Subcommittee: E55.12
Pages: 9
DOI: 10.1520/E3443-24